Acknowledging these limitations, our data identify a non-linear relationship between CD34+ cell dose and relapse risk among AML patients undergoing myeloablative allogeneic HCT with HLA-matched related or unrelated peripheral blood stem cells. This evidence concerns the gene CD34 and acute myeloid leukemia.